Sleepacta
Sleepacta is an Italian University of Pisa spin-off that markets the DORMI neural network, a CE Class I certified AI algorithm for sleep-wake cycle analysis delivered as-a-service via REST API. It serves hospitals, sleep clinics, pharmaceutical and medical technology firms, research institutions, and specialized practices across Italy and Europe.
- Company typePrivate
- Founded2017
- HeadquartersPisa, Italy
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Sleepacta does
Sleepacta is a privately held Italian medical-AI company founded in 2017 as a spin-off of the University of Pisa. Its core product, the DORMI algorithm, is a CE Class I certified neural network that performs automated classification of sleep-wake cycles from actigraphic data captured by validated wearable devices. The algorithm produces clinical metrics including total sleep time, sleep efficiency, wake after sleep onset, and a sleep regularity index, and has been validated against polysomnography in over 500 simultaneous registrations with documented 94%+ concordance. DORMI Apnea, a specialized module for nocturnal apnea risk screening, was launched in November 2023, and the company also markets BracDormi, a proprietary medical-grade actigraphy wearable.
The company distributes DORMI through a REST API as-a-service model that allows integration into healthcare platforms, hospital information systems, remote patient monitoring solutions, and partner clinic workflows. End customers span public and private hospital sleep centers (Azienda Ospedaliera S. Chiara di Trento, AOUP Pisa, SonoMed Pisa, Poliambulatorio San Giuseppe, Santagostino), research institutions (Fondazione Stella Maris IRCCS, University of Pisa SonnoLab, University of Amsterdam, CNR Bologna, SIN-DEM multicenter network), pharmaceutical and medical technology partners, pediatric neurology programs (Dravet Italia ONLUS), corporate wellness operators (Geico SpA), and a certified 'Quiet Place' hospitality partner (Il Palagio Vecchio). Over 54 partners and customers are cited, concentrated primarily in Italy with research collaborations extending to the Netherlands.
Revenue mechanics combine usage-based API analytics fees, hardware sales or leases of BracDormi, licensing and service agreements for specialized clinical applications, and research data services. Pricing is not publicly disclosed and contracts are negotiated bilaterally. Sleepacta is backed by an initial angel-style investment from SAMBA Dream in 2018 and a private equity round from Red Lions s.r.l. in 2021; both rounds are undisclosed. The company operates with 1-10 employees from its headquarters in Pisa and participates in major European sleep and physiology conferences to maintain scientific credibility among clinicians, researchers, and hospital procurement audiences.
Sleepacta firmographics
Firmographics- Name
- Sleepacta
- Legal name
- Sleepacta
- Website
- https://sleepacta.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sleepacta is an Italian University of Pisa spin-off that markets the DORMI neural network, a CE Class I certified AI algorithm for sleep-wake cycle analysis delivered as-a-service via REST API. It serves hospitals, sleep clinics, pharmaceutical and medical technology firms, research institutions, and specialized practices across Italy and Europe.
- Ownership category
- akta.pro rank
Sleepacta industry classification
Industry- Product category
- Digital Sleep Diagnostics Software
- SIC
- Instruments For Meas & Testing Of Electricity & Elec Signals (3825), Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)
- akta.pro secondary industries
- Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA), Ambulatory Sleep Medicine Centers (HLAFABAJ), Sleep Tech Wearables (CRACAIAG)
Keywords
Where Sleepacta is headquartered
LocationHeadquarters
- HQ city
- Pisa
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Sleepacta business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- DORMI API Analytics Service: DORMI is offered as-a-service via authenticated REST APIs. Healthcare providers, hospitals, clinics, and third-party software platforms can integrate the algorithm to analyze actigraphic data and receive clinical reports and sleep KPIs. Revenue is generated through API usage fees for algorithmic processing and reporting.
- Medical-Grade Wearable Devices: Sleepacta provides its own medical-grade activity tracking devices (bracelets) optimized for maximum performance in data quality, monitoring continuity, and operational simplicity. These devices are sold or leased to partners and end customers.
- B2B Technology Partnerships: Partnerships with pharmaceutical companies, medical technology firms, and hospital organizations for specialized algorithmic outputs tailored to specific use cases (e.g., sleep apnea screening, drug efficacy monitoring). Revenue generated through licensing and service agreements.
- Research Data Services: Raw data downloads available for research centers to support clinical research objectives, sharing the large volume of data acquired during years of research and clinical testing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | API-based algorithmic analysis service with certified medical device compliance |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Sleepacta product offering
Product offeringCore offering
Sleepacta develops and commercializes DORMI, a CE-certified AI neural network algorithm that analyzes actigraphic data from wearable devices to assess sleep-wake cycles. The algorithm is delivered as-a-service via authenticated REST APIs to hospitals, sleep clinics, pharmaceutical companies, research institutions, and partner clinics, and is complemented by the DORMI Apnea screening module and the proprietary BracDormi medical-grade wearable device.
Product overview
Sleepacta is a University of Pisa spin-off offering a portfolio of sleep diagnostics products centered on the Dormi AI algorithm. The core Dormi neural network processes raw accelerometric data from validated wearable devices to analyze sleep-wake cycles and generate clinical reports. This integrates via REST API into existing clinical systems or is accessible through the Dormi web application. Specialized offerings include Dormi Apnea for nocturnal apnea risk screening, the medical-grade BracDormi wearable device, and the SonnoLab research division for ongoing R&D.
Differentiator
Problem solved
Functional benefit
Brands
- Dormi: AI-powered neural network algorithm for sleep-wake cycle analysis, certified as a CE Class I medical device, delivered as-a-service via REST API for clinical and diagnostic applications.
- Dormi Apnea
- SonnoLab
Products and services
- DORMI DORMI is an AI-powered sleep analysis algorithm based on neural networks, trained on more than 20,000 actigraphic examinations and validated against polysomnography with 94%+ concordance. It is registered as a CE Class I medical device under EU MDR 2017/745 and is delivered as-a-service via authenticated REST APIs for integration into clinical systems, hospital platforms, and Remote Patient Monitoring applications. It is intended for healthcare providers, hospitals, clinics, pharmaceutical companies, and research institutions performing non-invasive sleep-wake cycle screening.
- DORMI Apnea DORMI Apnea is a specialized certified medical algorithm that estimates the risk of nocturnal apneas using the same actigraphic data input as the core DORMI service. It is targeted at dental, neurological, and pneumological clinical segments for screening and triage of patients at risk of sleep apnea.
- BracDormi BracDormi is Sleepacta's proprietary medical-grade wearable bracelet optimized for high-quality actigraphic data capture and continuous monitoring. It is sold or leased to partners requiring certified hardware that meets DORMI's strict qualitative criteria for acquisition continuity, sensor precision, and raw data access.
Quantifiable outcome
- 94%+ classification concordance with polysomnography (gold standard)
- +2 more outcomes
Companies that use Sleepacta
Customer profileNamed customers10 records
Segments5 records
Ideal customer profiles5 records
Sleepacta technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Sleepacta partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered major, core and minor.
- NAP Project Consortium (EU Horizon Europe)majorEuropean research project (€3M funding, €800K to University of Pisa) developing 'mini brain' organoids for monitoring sleep habits and early Parkinson's disease detection. Consortium includes University of Pisa (coordination), University of Freiburg, University of Amsterdam, Organotherapeutics GmbH, Atlas Neuroengineering, and Sleepacta.
- SantagostinomajorSantagostino healthcare network offers DORMI service through their insomnia treatment clinics. Partnership enables online ordering of DORMI service integrated with Santagostino's cognitive behavioral therapy programs for insomnia.
- Azienda Ospedaliera S. Chiara di TrentomajorClinical collaboration studying impact of continuous glucose monitoring sensors on sleep in pediatric Type 1 diabetes patients. 47 children/adolescents monitored via actigraphy with DORMI algorithm.
- Fondazione Stella Maris (IRCCS)majorScientific collaboration for non-invasive sleep monitoring in children with neuropsychiatric disorders. Fondazione Stella Maris uses DORMI for sleep screening supporting clinical assessment.
- SonnoLab - University of PisacoreSleepacta's R&D is developed within SonnoLab, located at the Institute of Physiology 'Giuseppe Moruzzi' at University of Pisa. This academic partnership drives validation and development of wearable sleep monitoring systems.
- University of AmsterdammajorCollaboration with Sleep and Memory Lab for development of indexes to non-invasively monitor sleep stages via actigraphic measurements. Prof. Umberto Olcese, Associate Professor, serves as academic advisor.
- SIN-DEM (Italian Neurology Association)majorMulticenter study on sleep and circadian alterations as objective markers of Mild Cognitive Impairment and Alzheimer's Disease, revealing sex differences.
- Dravet Italia ONLUSminorNon-invasive sleep monitoring project for patients with Dravet syndrome, a rare form of pediatric epilepsy, using DORMI's certified actigraphic system.
- CNR BolognaminorResearch collaboration with the National Research Council of Italy for sleep and circadian rhythm studies.
- Geico SpAminorCorporate wellness project involving employee sleep analysis using certified DORMI medical device to promote worker health and wellbeing.
- Il Palagio VecchiominorFirst 'Quiet Place' certified in Italy using DORMI to offer guests personalized sleep analysis and optimization services.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Sleepacta competitors and assessment
Company assessmentBroad incumbents
- Philips Respironics: Major incumbent offering polysomnography systems, CPAP/APAP devices, and sleep diagnostic platforms. Comparability stems from operating across the full sleep care continuum where Sleepacta targets non-invasive AI-based diagnostics as an alternative to PSG.
- ResMed: Global leader in sleep apnea therapy (CPAP) and connected sleep health. ResMed overlaps with Sleepacta through sleep diagnostics and remote patient monitoring ecosystems that increasingly incorporate AI-driven sleep analysis, though its core business is therapeutic hardware rather than actigraphy algorithms.
Direct peers
- Compumedics: Australia-based developer of PSG, actigraphy, and EEG-based sleep diagnostics used by hospitals and research institutions worldwide. Direct peer because it sells actigraphy hardware and analysis software targeting the same clinical sleep research and diagnostic market Sleepacta serves with DORMI.
- ActiGraph: Leading manufacturer of research-grade actigraphy wearables and the CentrePoint/ActiLife analysis platform used in clinical trials and academic sleep research. Direct peer because it sells both actigraphy hardware and analysis software into the same research and pharma customer segments as Sleepacta.
- Itamar Medical: Acquired by ZOLL/ResMed, Itamar markets WatchPAT, a wearable home sleep testing device for sleep apnea diagnosis. It is a direct peer in providing non-invasive, certified, wearable-based sleep diagnostics delivered to clinicians as an alternative to lab PSG.
Emerging players
- Dreem: AI-powered sleep headband combining EEG and actigraphy to deliver sleep staging and clinical-grade analytics. Comparable as an emerging player using AI/neural networks on wearable sensor data to deliver sleep analysis to clinicians and consumers, overlapping with DORMI's AI-actigraphy approach.
- Beacon Biosignals: AI-driven EEG analysis platform focused on neurological and sleep disorder drug development. Comparable as an emerging AI sleep/biomarker analytics company serving pharma and clinical research customers with algorithm-as-a-service offerings analogous to Sleepacta's API model.
- Oura: Consumer smart ring with sleep staging and readiness scoring. Comparable as a device-agnostic wearable platform where Sleepacta's algorithm could be deployed, and as an emerging player pushing clinically validated sleep features into the consumer segment.
- Eight Sleep: Smart mattress and sleep-tracking platform sold to consumers and corporate wellness buyers. Comparable as an emerging player bringing sleep analytics into wellness and corporate programs — a customer segment where Sleepacta also sells DORMI (e.g., Geico SpA corporate wellness deployment).
- Withings: Connected health devices including sleep-tracking mat and watches with health monitoring. Comparable as an emerging health-wearable platform that produces raw accelerometric signals Sleepacta's device-agnostic algorithm can potentially integrate with for sleep-wake classification.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Sleepacta social profiles
Digital presenceSleepacta compliance and trust
Trust signalCompliance3 records
Sleepacta financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sleepacta leadership team
Management profileNumber of profiles
Profiles9 records
Sleepacta funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sleepacta M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sleepacta
What does Sleepacta do?
Sleepacta develops and commercializes DORMI, a CE-certified AI neural network algorithm that analyzes actigraphic data from wearable devices to assess sleep-wake cycles. The algorithm is delivered as-a-service via authenticated REST APIs to hospitals, sleep clinics, pharmaceutical companies, research institutions, and partner clinics, and is complemented by the DORMI Apnea screening module and the proprietary BracDormi medical-grade wearable device.
Is Sleepacta a public or private company?
Sleepacta is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sleepacta founded?
Sleepacta was founded in 2017. It employs 1 to 10 people.
Where is Sleepacta based?
Sleepacta is headquartered in Pisa, Italy, in the Europe region.
How does Sleepacta make money?
Four revenue lines are on record. DORMI API Analytics Service is the primary driver. The others are medical-Grade Wearable Devices, B2B Technology Partnerships and research Data Services.
Who are Sleepacta's main competitors?
Broad incumbents on record are Philips Respironics and ResMed. Direct peers are Compumedics, ActiGraph and Itamar Medical. Emerging players are Dreem, Beacon Biosignals, Oura, Eight Sleep and Withings.
Does Sleepacta have an API?
Yes. Dormi offers authenticated REST API for sleep analysis. The API enables: partner/activity tracker/patient census management, activity tracker delivery management to partners and patients, auditing logs for actigraphic exams with raw-data recovery. The API is available as-a-service and integrates into third-party systems (web applications, mobile apps, clinical platforms, Remote Patient Monitoring systems). Output formats include JSON standard or Sleepacta certified format. No personal patient data is stored on the cloud infrastructure, ensuring GDPR compliance. Developer documentation is at partners.sleepacta.com/api_docs.
What industry is Sleepacta in?
Sleepacta's product category is Digital Sleep Diagnostics Software. Its primary akta.pro industry code is HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy), with a secondary code of HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV). Its SIC code is 3825.